You might also like

More about Antibody-Drug Conjugates

• Book details
• Synopsis
• Trending among others

You get 304 loyalty points

Book synopsis

This authoritative volume provides a holistic picture of antibody-drug conjugates (ADCs). Fourteen comprehensive chapters are divided into six sections including an introduction to ADCs, the ADC construct, development issues, landscape, IP and pharmacoeconomics, case studies, and the future of the field. The book examines everything from the selection of the antibody, the drug, and the linker to a discussion of developmental issues such as formulations, bio-analysis, pharmacokinetic-pharmacodynamic relationships, and toxicological and regulatory challenges. It also explores pharmacoecomonics and intellectual properties, including recently issued patents and the cost analysis of drug therapy. Case studies are presented for the three ADCs that have received FDA approval: gemtuzumab ozogamicin (Mylotarg®), Brentuximab vedotin (Adcetris®), and ado-trastuzumab emtansine (Kadcyla®), as well as an ADC in late-stage clinical trials, glembatumumab vedotin (CDX-011). Finally, the volume presents a perspective by the editors on the future directions of ADC development and clinical applications. Antibody-Drug Conjugates is a practical and systematic resource for scientists, professors, and students interested in expanding their knowledge of cutting-edge research in this exciting field.§

Book details

Book category Books in English Technology, engineering, agriculture Industrial chemistry & manufacturing technologies Industrial chemistry

• Full title: Antibody-Drug Conjugates
• Subtitle: The 21st Century Magic Bullets for Cancer
• Author: Jeffrey Wang, Wei-Chiang Shen, Jennica L. Zaro
• Language: English
• Binding: Hardback
• Number of pages: 252
• EAN: 9783319130804
• ISBN: 3319130803
• ID: 09030176
• Publisher: Springer International Publishing AG
• Weight: 552 g
• Dimensions: 246 × 164 × 19 mm
• Date of publishing: 06. March 2015

Trending among others

---

---

---